Laboratory Software Validation, CSV & CSA
Request independent support for computerized system validation (CSV), qualification and risk-based software assurance. Validation belongs to the configured system, intended use and controlled process—not to a product label. Laboratory Vortex coordinates requests; it does not certify systems.
Scope the lifecycle, not just the test scripts
- Define intended use, regulated records, process impact, user requirements and accountable system owner.
- Assess suppliers, configuration, interfaces, infrastructure and migration; agree which supplier evidence can be leveraged and what needs independent verification.
- Use documented risk assessment to select testing and assurance activities; maintain traceability to critical requirements.
- Plan deviations, release approval, training, change control, periodic review, backup/restore evidence, retention and retirement.
GAMP 5, CSV and software qualification
GAMP 5 is ISPE industry guidance, not legislation or a certification. A risk-based approach can use supplier documentation and proportionate evidence, while your organization remains responsible for intended-use suitability. IQ/OQ/PQ terminology may be used in a qualification strategy; a set of scripts alone does not establish ongoing control.
FDA 21 CFR Part 11 and data integrity
Assess whether electronic records/signatures fall within Part 11 and applicable predicate rules. The system's configured controls and procedures matter: user access, record protection, audit trails, signature meaning, review, retention and retrieval. A vendor's 'Part 11 ready' statement does not establish your implementation's compliance.
- Confirm attributable, legible, contemporaneous, original and accurate records, with completeness, consistency, endurance and availability.
- Verify audit-trail generation, review responsibilities, administrative access and segregation of duties.
- Test record export, readable retention, backup restoration and migration reconciliation.
Computer software assurance (CSA): qualified scope
FDA's final guidance issued February 3, 2026 addresses software used in medical-device production and quality management systems. It recommends a risk-based assurance approach; it is not a blanket exemption from validation or a replacement for obligations across pharmaceutical, clinical and research laboratories. Check the current FDA source and your applicable regulatory framework.
What to include in a request
- System category/version, intended use and applicable regulations
- Users/sites, deployment, interfaces, records and migration scope
- Existing validation evidence, supplier support, deliverables and timeline